T ?/? hepatosplenic lymphoma in a heart transplant patient after an epstein-barr virus positive lymphoproliferative disorder

Kraus, Madeleine D.; Crawford, David F.; Kaleem, Zahid; Shenoy, Shalini; MacArthur, Craig A.; Longtine, Janina A.

doi:10.1002/(sici)1097-0142(19980301)82:5<983::aid-cncr26>3.0.co;2-w

Cited by 54 publications

(33 citation statements)

References 31 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…55 Eight of our patients had remarkable medical histories. Four had received long-term immunosuppressive therapy for kidney transplantation, an observation in accordance with previous reports of HS␥␦TCL as a late-onset posttransplantation lymphoproliferative disorder 7,14,15,19,22,24,56,57 of host origin. 20 Two other patients had falciparum malaria, 1 was monitored for systemic lupus erythematosus, and 1 was found to have HS␥␦TCL during therapy delivered for EBV-positive Hodgkin disease.…”

Section: Discussionsupporting

confidence: 89%

Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Belhadj

Reyes²,

Farcet³

et al. 2003

Blood

404

399

View full text Add to dashboard Cite

We report on the characteristics of 21 patients with hepatosplenic ␥␦ T-cell lymphoma (HS␥␦TCL), an entity recognized since 1994 in the Revised European American Lymphoma (REAL) classification. Median age was 34 years. Patients had splenomegaly (n ‫؍‬ 21), hepatomegaly (n ‫؍‬ 15), and thrombocytopenia (n ‫؍‬ 20). Histopathologic findings were homogeneous and showed the presence of medium-sized lymphoma cells within the sinusoids of splenic red pulp, liver, and bone marrow. Marrow involvement was usually mild but could be demonstrated by phenotyping in all patients. Cells were CD3 ؉ CD5 ؊ , expressed the ␥␦ T-cell receptor, and had a nonactivated cytotoxic cell phenotype (TIA-1 ؉ ,

show abstract

Section: Discussionsupporting

confidence: 89%

Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Belhadj

Reyes²,

Farcet³

et al. 2003

Blood

404

399

View full text Add to dashboard Cite

show abstract

“…15 A known phenomenon in peripheral T cell lymphomas and also documented in areas invaded by malignant hepatosplenic ␥␦ T cells is erythrophagocytosis. [1][2][3]8,18,22,23,26 Besides peripheral cytopenia, this feature may be another indicator for active cytokine production by the tumor. 18 Tumor necrosis factor ␣ has been presumed to be responsible for histiocyte activation and subsequent erythrophagocytosis in EBV transformed T cell lymphomas.…”

Section: Histopathologymentioning

confidence: 99%

Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990

2000

View full text Add to dashboard Cite

Peripheral T cell lymphomas are a heterogeneous group of post-thymic, mature lymphoid malignancies, accounting for approximately 10-15% of all non-Hodgkin's lymphomas. A rare entity within this group is represented by hepatosplenic ␥␦ T cell lymphoma, which is characterized by primary extranodal disease with typical sinusoidal or sinusal infiltration of the liver and the spleen, respectively, by expression of the T cell receptor ␥␦ chain, and by a number of other frequent clinicopathological features including aggressive course of disease. In contrast to these common attributes some biologic characteristics such as expression of cytotoxic proteins and cytotoxic activity have been controversial. In this review, clinicopathological, immunophenotypical, molecular biological, cytogenetical and biological findings, and diagnostic and therapeutic difficulties in hepatosplenic ␥␦ T cell lymphoma are discussed. Leukemia (2000) 14, 991-997.

show abstract

“…In addition, EBV infection may play an indirect pathogenic role by stimulating and expanding gd T-cells. There has been a case report of HSTL arising 4 months after EBV-positive polymorphic B-cell PTLD [8], and another case report of EBVpositive B-cell PTLD associated with significant expansion of gd T-cells [19].…”

Section: Discussion and Literature Reviewmentioning

confidence: 99%

Post‐transplant hepatosplenic T‐cell lymphoma successfully treated with hyperCVAD regimen

et al. 2007

View full text Add to dashboard Cite

Hepatosplenic T‐cell lymphoma (HSTL) is an aggressive lymphoma. In post‐transplant immunosuppressed patients, HSTL is usually rapidly fatal. We report successful treatment of post‐transplant HSTL in a 50‐year‐old renal allograft recipient by reducing immunosuppression and using intensive chemotherapy consisting of alternating cycles of HyperCVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and MTX/HiDAC (methotrexate, Ara‐C). Remission is ongoing at 8+ years. Literature review identified another 20 cases of HSTL in solid organ transplant recipients: median survival was 4 months; no other patients survived beyond 12 months. Bone marrow involvement was universal, but changes were often subtle: 6 of 12 cases had nondiagnostic examinations earlier on. High index of suspicion may lead to more timely diagnosis of this uncommon form of post‐transplant lymphoproliferative disorder, and treatment with intensive chemotherapy such as HyperCVAD may be curative. Am. J. Hematol., 2008. © 2007 Wiley‐Liss, Inc.

show abstract

T ?/? hepatosplenic lymphoma in a heart transplant patient after an epstein-barr virus positive lymphoproliferative disorder

Cited by 54 publications

References 31 publications

Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990

Post‐transplant hepatosplenic T‐cell lymphoma successfully treated with hyperCVAD regimen

Contact Info

Product

Resources

About